×

A New Watchlist

We’ve updated Watchlist! The changes include a new, responsive design featuring extended-hours data and more news. Learn more.
    |
    XLV U.S.: NYSE Arca

    Health Care Select Sector SPDR ETF

    XLVUS
    After Hours
    Back To Top
    Last Updated: Aug 23, 2019 7:20 p.m. EDT Delayed quote

    $88.75

    -0.01 -0.01%
    After Hours Volume: 82K
    Financial Services -2.13%
    Close Chg Chg %
    $88.76 -2.10 -2.31% -2.10 -2.31%
    Advanced Charting
    • $
    • %
    • Vol
    Advanced Charting
    99.03% vs Avg.
    Volume: 9.8M 65 Day Avg. - 9.9M
    Open: 90.70
    Close: 88.76
    88.32 Day Low/High 91.04
    Day Range
    80.61 52 Week Low/High 96.06

    Your Watchlist

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    Key Data

    • Open $90.70
    • Day Range 88.32 - 91.04
    • 52 Week Range 80.61 - 96.06
    • Market Cap n/a
    • Shares Outstanding 188.87M
    • Total Net Assets $17.21B
    • Beta n/a
    • NAV $88.75
    • NAV Date Aug 23, 2019
    • Net Expense Ratio 0.13%
    • Turnover % 5%
    • Yield 1.67%
    • Dividend $0.40
    • Ex-Dividend Date Jun 21, 2019
    • Average Volume 9.92M

    Lipper Leader

    YTD Lipper Ranking:Quintile 5 (82nd percentile)
    • 3 Total Returns
    • 3 Consistent Return
    • 4 Preservation
    • 4 Tax Efficiency
    • 5 Expense

    Lipper Leaders Key

    • Highest
    • 5
    • 4
    • 3
    • 2
    • 1
    • Lowest

    Recent News

    • MarketWatch
    • WSJ

    Medtronic's stock surges to record, paces S&P 500 gainers after upbeat results and outlook

    Shares of Medtronic PLC ran up 4.8% toward a record high in morning trading, to top the S&P 500's list of gainers, after the medical technology company reported second-quarter results that beat expectations and raised its full-year profit outlook. The stock was also the leading gainer within the SPDR Health Care Select Sector ETF . The stock has now run up 8.1% amid a 4-session win streak, which would be the best 4-day stretch since it ran up 10.2% in the four days ending Oct. 2, 2015. SVB Leerink analyst Danielle Antalffy said that despite a decline in the cardiac and vascular group business segment, which is Medtronic's largest by revenue, the company still delivered a total revenue beat, "which we think highlights the strength of [Medtronic's] broad-based business model." The stock has hiked up 20% year to date, while the health care ETF has tacked on 5.5% and the S&P 500 has advanced 16%.

    Pfizer's stock sinks again, toward 14-month low to pace 'Dow's' losers

    Shares of Pfizer Inc. dropped 3.6% in afternoon grading Monday, putting them on track to close at a 14-month low, as the drugmaker extends the rough patch in the wake of its second-quarter earnings report and announcement to merge its Upjohn business with Mylan Inc. . The stock, which was the biggest decliner among the Dow Jones Industrial Average's components, is headed for the 9th decline in 11 sessions since the company reported earnings on July 29. During the stretch, the stock has shed 18.6%, which puts it on track for the lowest close since May 9 ,2018. It has now shed 19.6% year to date, while the SPDR Health Care Select Sector ETF has gained 4.7% and the Dow Jones Industrial Average [s; djia] has advanced 11.4%.

    Read full story
    Premium

    Charting a volatility spike, S&P 500 whipsaws at the breakdown point (2,912)

    Earnings recession is nearly certain with 90% of S&P 500 having reported

    An earnings recession is now nearly certain. With 456 of the 505 S&P 500 components, or 90.3%, having reported second-quarter earnings through Friday morning, the blended year-over-year EPS growth estimate is negative 0.72%, with six of the 11 sectors showing declines, according to FactSet. That means the remaining 49 companies have to report EPS growth on average of 6.70% to lift the S&P 500 growth to flat. A Q2 earnings decline would follow a 0.21% decline in the first quarter; a recession is generally defined as two consecutive quarter of negative growth. The last time there were back-to-back quarters of negative EPS growth was the second quarter of 2016. For Q2, the sectors with the biggest EPS declines are materials at negative 17.88% and industrials at negative 10.19%, according to FactSet, while the biggest increase is health care at positive 8.85%. Meanwhile, the third-quarter EPS growth estimate is currently negative 3.31%. Despite the EPS declines, the S&P 500, which shed 0.7% in morning trading Friday, has gained 1.6% over the past three months and 16.4% year to date.

    Perrigo's stock surges after profit and revenue decline less than expected, outlook affirmed

    Shares of Perrigo Co. surged 6.0% in premarket trading Thursday, after the over-the-counter health and wellness products company reported second-quarter profit and revenue that beat expectations, and affirmed its full-year outlook. Net income fell to $9 million, or 7 cents a share, from $36 million, or 26 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS fell to 86 cents from $1.22, above the FactSet consensus of 79 cents. Sales declined 3.1% to $1.15 billion but topped the FactSet consensus of $1.13 billion, as consumer self-care America sales fell 2.5%, consumer self-care international sales declined 8.5% and prescription pharmaceuticals sales rose 3.4%. The company affirmed its 2019 adjusted EPS outlook of $3.75 to $4.05. The stock has run up 30.3% year to date through Wednesday, while the S&P 500 has gained 15.0%.

    Read full story

    Charting a damaging August downdraft, S&P 500 violates major support

    Read full story
    Premium

    Charting a damaging August downdraft, S&P 500 violates major support

    Bausch Health's stock surges as revenue rises in line with expectations, but outlook raised

    Shares of Bausch Health Companies Inc. rallied 3.0% in premarket trading Tuesday, after the health care products company reported second-quarter revenue that rose in line with expectations and raised its full-year profit outlook. The net loss narrowed to $171 million, or 49 cents a share, from $873 million, or $2.49 a share, in the same period a year ago as operating results increased while interest expense and loss on extinguishment of debt declined. Excluding non-recurring items, adjusted net income rose to $372 million from $327 million, but the company did not provide adjusted per-share figures. Total revenue rose to $2.152 billion from $2.128 billion a year ago, in line with the FactSet consensus of $2.151 billion, as Bausch & Lomb/international sales miss expectations while Salix sales beat. For 2019, the company raised its revenue guidance range to $8.40 billion to $8.60 billion from $8.35 billion to $8.55 billion. The stock has run up 26.3% year to date through Monday, while the SPDR Health Care Select Sector ETF has gained 2.8% and the S&P 500 has advanced 13.5%.

    Humana's stock jumps after profit and revenue rise above expectations

    Shares of Humana Inc. jumped 2.3% in premarket trading Tuesday, after the health care company reported second-quarter profit and revenue that rose above expectations and provided an upbeat full-year outlook. Net income was $1.23 billion, or $6.94 a share, after income of $19 million, or $1.39 a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS came to $6.05, well above the FactSet consensus of $5.31. Revenue rose to $16.25 billion from $14.26 billion a year ago, to beat the FactSet consensus of $15.93 billion. For 2019, the company now expects adjusted EPS of $17.60, compared with the FactSet consensus of $17.48, and raised its Medicare Advantage membership growth guidance range to 480,000 to 500,000 members. The stock has slipped 0.7% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has advanced 6.4% and the S&P 500 has climbed 20.2%.

    HCA Healthcare's stock falls after surprise profit decline, revenue comes up shy

    Shares of HCA Healthcare Inc. dropped 7.1% in premarket trading Tuesday, after the hospital operator reported a surprise decline in second-quarter profit and revenue that came up a bit shy. Net income fell to $783 million, or $2.25 a share, from $820 million, or $2.31 a share, in the same period a year ago. Earnings per share included a 4-cent gain from facilities sales. The FactSet EPS consensus was $2.47. Revenue rsoe to $12.60 billion from $11.53 billion a year ago, but was just below the FactSet consensus of $12.62. Same-facility admissions increased 2.1%, same-facility emergency room visits grew 3.0% and same-facility inpatient surgeries declined 0.1%. For 2019, the company expects EPS of $10.25 to $10.65, surrounding the FactSet consensus of $10.40, and revenue of $50.5 billion to $51.5 billion, compared with expectations of $51.0 billion. The stock has rallied 17.4% year to date through Monday, while the SPDR Health Care Select Sector ETF has tacked on 6.9% and the S&P 500 has advanced 20.5%.

    Eli Lilly's stock jumps after profit and revenue beats, raised guidance

    Shares of Eli Lilly & Co. rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion, or $1.44 a share, after a loss of $259.9 million, or 25 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS rose to $1.50 from $1.48, above the FactSet consensus of $1.45. Revenue rose 1% to $5.64 billion, beating the FactSet consensus of $5.58 billion. Trulicity sales climbed 32% to $1.03 billion, just below the FactSet consensus of $1.08 billion, while Humalog sales fell 12% to $677.6 million but beat expectations of $659.7 million. For 2019, the company raised its adjusted EPS guidance range to $5.67 to $5.77 from $5.60 to $5.70. The stock has lost 6.1% year to date through Monday, while the SPDR Health Care Select Sector ETF has gained 6.9% and the S&P 500 has rallied 20.5%.

    DaVita's stock rallies after profit outlook raised

    Shares of DaVita Inc. rallied 4.2% in premarket trading Monday, after the dialysis services company raised its profit outlook, as it looks to update investors ahead of the expected modified "Dutch auction" to buy back up to $1.2 billion worth of its shares. The company said it now expects second-quarter operating income of $460 million to $465 million, which is above the FactSet consensus of $398 million. DaVita also expects second-quarter non-acquired treatment growth of 2.1% and revenue per treatment to increase by about $1.60 from the first quarter to $350. For 2019, the company raised its adjusted operating income guidance to $1.64 billion to $1.70 billion from $1.54 billion to $1.64 billion. Separately, the company said the auction for its shares will be at a price per share of "not less than $53.50 nor greater than $61.50." The stock closed Friday at $56.05. It has gained 9.7% over the past three months, while the SPDR Health Care Select Sector ETF has advanced 6.7% and the Dow Jones Industrial Average has tacked on 2.4%.

    Read full story

    J&J earnings preview: Wall Street is still optimistic despite company’s legal issues

    Read full story

    Health care is one of the stock market’s healthiest sectors right now

    Corrected

    Health Catalyst sets IPO terms, to value company at up to $784 million

    Health Catalyst Inc. disclosed Friday terms for its initial public offering, in which the Salt Lake City-based data and analytics technology services for the health care industry is looking to raise up to $138 million. The company is offering 6 million shares in the IPO, which is expected to price between $20 and $23. The stock is expected to list on the Nasdaq Global Select Market under the ticker symbol "HCAT." With 34.1 million shares outstanding after the IPO, the company would be valued at up to $783.8 million. Goldman Sachs, J.P. Morgan and William Blair are the lead underwriters. The company estimates second-quarter 2019 losses from operations of $10.3 million to $9.3 million on revenue of $19.6 million to $20.1 million, after a loss of $18.8 million on revenue of $10.7 million in same period a year ago. The company is looking to go public at a time the Renaissance IPO ETF has gained 4.6% over the past three months, while the SPDR Health Care Select Sector ETF has advanced 3.0% and the S&P 500 has tacked on 3.3%.

    DaVita, American Renal stocks bounce after President Trump signs executive order on kidney disease

    Shares of DaVita Inc. bounced 4.3% in afternoon trading Wednesday, after President Trump signed an executive order on kidney disease, aimed at cutting costs of dialysis treatments. The stock had tumbled 9.8% over the past two sessions in anticipation of the executive order. DaVita said late Tuesday that the Trump administration's initiatives are expected to support DaVita's investments to prevent kidney disease, encourage home kidney care and improve kidney transplantation rates. "We've been investing in capabilities to deliver holistic care that addresses our patients' needs beyond kidney disease, such as mental health, social services and nutrition," said Chief Executive Javier Rodriguez. "We will continue to work with the Administration and Congress to launch programs that address broader care opportunities." Shares of fellow dialysis services provider American Renal Associates Holdings Inc. rsoe 1.6%, after plunging 9.6% on Tuesday. Year to date, DaVita's stock has gained 6.8% and American Renal shares have plummeted 40.6%, while the SPDR Health Care Select Sector ETF has tacked on 8.1% and the S&P 500 has advanced 19.5%.

    Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing

    Shares of health companies were down Monday, with both the Health Care Select Sector SPDR Fund ETF and the SPDR S&P Pharmaceuticals ETF falling 0.6% in morning intraday trade. Shares of Cardinal Health Inc. led the losers in the S&P 500's health-care ETF, falling 3.1% after the company said CFO Jorge Gomez would leaving the company, followed by declines in shares of Incyte Corp , Alexion Pharmaceuticals Inc. , and Biogen Inc. , Regeneron Pharmaceuticals Inc. and Amgen Inc. . The dip in health-care stocks comes after President Trump's announcement Friday that he was planning to soon issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries. "Our guess is drug stocks may be initially pressured this week," Jefferies health-care trading desk strategist Jared Holz wrote in an email to clients on Sunday evening. However, "feedback already suggests investors believe the executive order, if it comes to pass, will only be relevant for a handful of drugs (those that are very significant in revenue and administered in a physician's office)... at least at the onset," he wrote. The drop in health shares comes amid a broader decline in U.S. stocks, as investors grapple with doubts about whether the Federal Reserve will still cut interest rates after a strong U.S. jobs report Friday. The S&P 500 was down 0.4% Monday morning. The index has gained 18.8% in the year to date.

    Read full story
    Premium

    Charting a late-month holding pattern, S&P 500 maintains major support (again)

    Read full story

    Allergan acquisition is ‘a major bailout’ for shareholders, according to analysts

    Allergan's stock soars after WSJ report AbbVie near a buyout deal for a 45% premium

    Shares of Allergan PLC soared 35% toward an 8-month high in premarket trading Tuesday, after The Wall Street Journal reported that AbbVie Inc. was close to a deal to buy the pharmaceutical company. AbbVie's stock dropped 6.0% ahead of the open. The WSJ report said AbbVie would pay $188 in cash and stock for each Allergan share outstanding, which is 45% above Monday's closing price of $129.57. With 327.8 million shares outstanding as of May 3, the deal would value Allergan at about $61.6 billion. AbbVie's market capitalization as of Monday's close was $115.98 billion. Allergan's stock has declined 24.3% over the past 12 months through Monday and AbbVie shares have lost 15.7%, while the SPDR Health Care Select Sector ETF has climbed 10.8% and the S&P 500 has advanced 8.4%.

    Read full story

    Amazon Is Now a $700 Billion Stock-Market Gorilla

    • on The Wall Street Journal
    Read full story

    Health-Care Stocks Get a Boost From Senate Bill Rollout

    • on The Wall Street Journal
    Read full story

    Biotech ETFs Sink After House Passage of Health-Care Bill

    • on The Wall Street Journal
    Read full story

    Health-Care Investors Are Too Complacent

    • on The Wall Street Journal
    Read full story

    Goldman Says Buy Health-Care, Retail Volatility Before Trump Address

    • on The Wall Street Journal
    Read full story

    Stock Pickers’ Delight: S&P 500 Correlations Plunge

    • on The Wall Street Journal
    Read full story

    Will Funds Outperform in 2015?

    • on The Wall Street Journal
    Read full story

    Health and Tech Funds Step Up

    • on The Wall Street Journal
    Read full story

    ETF Ideas for Banks in a Rising-Rate Environment

    • on The Wall Street Journal
    Read full story

    A Bet on Health Care May Help Offset Tuition Increases

    • on The Wall Street Journal
    Read full story

    Sector ETFs Come in Beginner, Moderate and Advanced Versions

    • on The Wall Street Journal
    Read full story

    A Good Prognosis for Health-Care Stocks

    • on The Wall Street Journal
    Read full story

    Is This a Bubble?

    • on The Wall Street Journal
    Read full story

    Profiting From the Standoff

    • on The Wall Street Journal

    Crystal Ball: Test Your Prediction Skills

    • on The Wall Street Journal

    Options Traders Position for Health-Care Pullback

    • on The Wall Street Journal

    The Good Leads

    • on The Wall Street Journal
    Read full story

    U.S. Stocks Seem Like a Sound Bet

    • on The Wall Street Journal
    Read full story

    Health-Care Investors/Tea Leaf Readers Turn To The Supreme Court

    • on The Wall Street Journal

    Amazon.com, Health Care SPDR Select Sector Fund: Money Flow Leaders (AMZN, XLV)

    • on The Wall Street Journal

    Recent News

    • Other News
    • Press Releases

    Market Volatility Bulletin: Fed Funds Futures Market Are Tamping Down Rate Cut Expectations

    Market Volatility Bulletin: Fed Funds Futures Market Are Tamping Down Rate Cut Expectations

    • on Seeking Alpha

    IHI: Medical Device Bull Market To End Soon

    IHI: Medical Device Bull Market To End Soon

    • on Seeking Alpha

    Smart Portfolios, LLC Buys JPMorgan Ultra-Short Income ETF, First Trust Enhanced Short Maturity ...

    Smart Portfolios, LLC Buys JPMorgan Ultra-Short Income ETF, First Trust Enhanced Short Maturity ETF, iShares MSCI EAFE ETF, Sells Vanguard FTSE Emerging Markets ETF, Invesco BuyBack Achievers ETF, iShares Floating Rate Bond ETF

    • on GuruFocus.com

    Citizens & Northern Corp Buys Johnson & Johnson, eBay Inc, Health Care Select Sector ...

    Citizens & Northern Corp Buys Johnson & Johnson, eBay Inc, Health Care Select Sector SPDR Fund, Sells Wells Fargo, Charles Schwab Corp, CVS Health Corp

    • on GuruFocus.com

    Sunrise Partners Limited Partnership Buys JPMorgan Chase, Apple Inc, The Communication ...

    Sunrise Partners Limited Partnership Buys JPMorgan Chase, Apple Inc, The Communication Services Select Sector SPDR Fund, Sells Utilities Select Sector SPDR Fund, Consumer Staples Select Sector SPDR Fund, CVS Health Corp

    • on GuruFocus.com

    Hilltop Holdings Inc. Buys iShares TIPS Bond ETF, Vanguard Total Stock Market ETF, iShares Core ...

    Hilltop Holdings Inc. Buys iShares TIPS Bond ETF, Vanguard Total Stock Market ETF, iShares Core MSCI EAFE ETF, Sells iShares MBS ETF, Vanguard Dividend Appreciation ETF, SPDR Barclays High Yield Bond ETF

    • on GuruFocus.com

    Financial Architects, Inc Buys Invesco S&P 500 Pure Growth ETF, Invesco BulletShares 2021 ...

    Financial Architects, Inc Buys Invesco S&P 500 Pure Growth ETF, Invesco BulletShares 2021 Corporate Bond ETF, Invesco S&P 500 Equal Weight Technology ETF, Sells JPMorgan Chase, Wells Fargo, Goldman Sachs Group Inc

    • on GuruFocus.com

    Don't Fear Yield Curve Inversion, Play These Top ETFs Instead

    Inverted yield curve is not as scary as it seems to be. Wall Street staged a rally on many such occasions. So, investors can easily bet on these top-ranked ETFs.

    • on Zacks.com

    BW Gestao de Investimentos Ltda. Buys iShares MSCI Brazil Capped ETF, Health Care Select Sector ...

    BW Gestao de Investimentos Ltda. Buys iShares MSCI Brazil Capped ETF, Health Care Select Sector SPDR Fund, Facebook Inc, Sells Petroleo Brasileiro SA Petrobras, Bank of America Corporation, Nexa Resources SA

    • on GuruFocus.com

    Susquehanna International Group Ltd. Buys iShares J.P. ...

    Susquehanna International Group Ltd. Buys iShares J.P. Morgan USD Emerging Markets Bond ETF, Health Care Select Sector SPDR Fund, iShares MSCI Mexico Capped ETF, Sells iShares MSCI Hong Kong ETF, Anheuser-Busch InBev SA/NV, iShares MSCI EAFE ETF

    • on GuruFocus.com

    Healthcare And Biotechnology Dashboard - Update

    Healthcare And Biotechnology Dashboard - Update

    • on Seeking Alpha

    Act Two Investors LLC Buys CBS Corp, Health Care Select Sector SPDR Fund, NXP Semiconductors ...

    Act Two Investors LLC Buys CBS Corp, Health Care Select Sector SPDR Fund, NXP Semiconductors NV, Sells Citigroup Inc, Allergan PLC, Industrial Select Sector SPDR Fund

    • on GuruFocus.com

    Elliott Management Buys Marathon Petroleum Corp, Health Care Select Sector SPDR Fund, DXC ...

    Elliott Management Buys Marathon Petroleum Corp, Health Care Select Sector SPDR Fund, DXC Technology Co, Sells Sempra Energy, Hess Corp, Altaba Inc

    • on GuruFocus.com

    Conventional Equity Funds Witness Outflows In July, While Equity ETFs Attract Net New Money

    Conventional Equity Funds Witness Outflows In July, While Equity ETFs Attract Net New Money

    • on Seeking Alpha

    Kepos Capital LP Buys Consumer Staples Select Sector SPDR Fund, Liberty Broadband Corp, Health ...

    Kepos Capital LP Buys Consumer Staples Select Sector SPDR Fund, Liberty Broadband Corp, Health Care Select Sector SPDR Fund, Sells Altaba Inc, Celgene Corp, Red Hat Inc

    • on GuruFocus.com

    Health Care Sector Innovation And Insight

    Health Care Sector Innovation And Insight

    • on Seeking Alpha

    Buy Infrastructure Equities For Yield And Insulation From Today's Troubled Times

    Buy Infrastructure Equities For Yield And Insulation From Today's Troubled Times

    • on Seeking Alpha

    Duality Advisers, Lp Buys Health Care Select Sector SPDR Fund, SPDR S&P Biotech ETF, ...

    Duality Advisers, Lp Buys Health Care Select Sector SPDR Fund, SPDR S&P Biotech ETF, Utilities Select Sector SPDR Fund, Sells PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, SPDR S&P Regional Banking ETF

    • on GuruFocus.com

    Cabana Llc Buys iShares Select Dividend ETF, iShares MSCI Emerging Markets ETF, Health Care ...

    Cabana Llc Buys iShares Select Dividend ETF, iShares MSCI Emerging Markets ETF, Health Care Select Sector SPDR Fund, Sells Consumer Discretionary Select Sector SPDR Fund, iShares Russell 2000 Value ETF, SPDR Gold Trust

    • on GuruFocus.com

    Gerber Kawasaki Wealth & Investment Management Buys Health Care Select Sector SPDR Fund, ...

    Gerber Kawasaki Wealth & Investment Management Buys Health Care Select Sector SPDR Fund, Blackstone Group Inc, Prologis Inc, Sells Control4 Corp, iShares Nasdaq Biotechnology Index Fund, iShares Core MSCI EAFE ETF

    • on GuruFocus.com

    XLV, GBF: Big ETF Outflows

    XLV, GBF: Big ETF Outflows

    • on MarketNewsVideo.com

    XLV, EGPT: Big ETF Outflows

    XLV, EGPT: Big ETF Outflows

    • on MarketNewsVideo.com

    Health Care Select Sector Spdr $XLV Technical Update

    • on Stock Traders Daily

    XLV, SZNE: Big ETF Inflows

    • on MarketNewsVideo.com

    XLV, FLN: Big ETF Outflows

    • on MarketNewsVideo.com

    Monday's ETF Movers: IGV, XLV

    • on MarketNewsVideo.com

    Top 10 Holdings

    Company Symbol Total Net Assets
    Johnson & Johnson JNJ 10.11%
    UnitedHealth Group Inc. UNH 6.92%
    Pfizer Inc. PFE 6.3%
    Merck & Co. Inc. MRK 6.25%
    Abbott Laboratories ABT 4.49%
    Medtronic PLC MDT 4%
    Amgen Inc. AMGN 3.33%
    Thermo Fisher Scientific Inc. TMO 3.25%
    AbbVie Inc. ABBV 2.88%
    Eli Lilly & Co. LLY 2.75%
    View more holdings As of 07/31/2019

    ETF Details

    Category Health/Biotech
    Portfolio Style Health/Biotech
    Fund Status Open
    Fund Inception December 16, 1998
    Managers
    Hancock
    Feehily
    Schneider

    Investment Policy

    The Fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the Health Care Select Sector Index. Under normal market conditions, the fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. (See Full Profile)

    Distribution History

    Date Income Distribution
    YTD $0.73
    2018 $1.36
    2017 $1.21
    2016 $1.1
    2015 $1.03
    2014 $0.92
    2013 $0.84
    2012 $0.8
    2011 $0.68
    2010 $0.57
    2009 $0.57